Clinical trials: Prostate Cancers
Prostate Cancer
68Ga-RM2 for PET/CT of Gastrin Releasing Peptide Receptor (GRPr) Expression in Prostate Cancer
The purpose of this study is to see if a new diagnostic research agent named 68Ga-RM2 can show prostate cancer on a PET/CT scan.
- Trial name
- NCT02559115
- Testing
- 68Ga-RM2 (RM2), PET/CT Scan
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Small Cell Prostate Cancer, Neuroendocrine Prostate Cancer
A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
This study will evaluate the response rate of MLN8237 in patients with histologically confirmed or clinically suspected metastatic neuroendocrine prostate cancer (NEPC).
- Conditions
- Small Cell Prostate Cancer, Neuroendocrine Prostate Cancer, Prostate Adenocarcinoma Plus > 50% Immunohistochemical Staining for Neuroendocrine Markers
- Trial name
- NCT01799278
- Testing
- MLN8237
- Where
- 8 sites in United States
- Volunteers
- 60 people
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer
Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC)
Eligible patients will be enrolled in one of 4 cohorts where each cohort will allow 3 patients to be on study. Patients will receive both study drugs on escalated dosing schedule until the maximum of 400 mg PO BID is reached for…
- Trial name
- NCT00424385
- Testing
- Gleevec + Sorafenib
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Oncology Specialists, S.C.
Prostate Cancer
Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer
This is a single arm study of 11 men with treatment refractory metastatic Castrate Resistant Prostate Cancer (CRPC) who will receive temsirolimus IV at a dose of 25 mg weekly until progression.
- Trial name
- NCT00887640
- Testing
- Temsirolimus, Diphenhydramine
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Duke University
Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
Study of NGM120 in subjects with advanced solid tumors and pancreatic cancer (Part 1 and 2) and metastatic castration resistant prostate cancer (Part 3).
- Conditions
- Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer, Melanoma
- Trial name
- NCT04068896
- Testing
- NGM120 30mg, NGM120 100mg, NGM120 30mg with Gemcitabine and Abraxane
- Where
- 20 sites in United States
- Volunteers
- 89 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Prostate Cancer Metastatic to Bone
Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone
This is a phase IIa, open label, single arm, and prospective study of hormone therapy-naïve men with oligometastatic prostate cancer to the bone.
- Trial name
- RROPE (NCT03304418)
- Testing
- Radium Ra 223 Dichloride, Radiation
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Utah
Castrate Resistant Prostate Cancer, Chemotherapy Naive Prostate Cancer
Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
This is an open label randomized phase II study for prostate cancer patients who have disease progression after hormonal therapy.
- Conditions
- Castrate Resistant Prostate Cancer, Chemotherapy Naive Prostate Cancer, Prostate Cancer
- Trial name
- NCT01313559
- Testing
- Pasireotide, Everolimus, Laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Castrate-resistant Prostate Cancer
Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer
This is a multi-national, multi-center, open-label, single-arm extension study for the prolongation of bone metastasis-free survival in men with hormone-refractory (androgen independent) prostate cancer.
- Trial name
- NCT01824342
- Testing
- Denosumab
- Where
- 9 sites in Czechia, United Kingdom
- Volunteers
- 18 people
- Sponsor
- Amgen
Prostate Cancer
PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer
The purpose of this study is to assess the safety and efficacy of avelumab in patients with metastatic neuroendocrine-like prostate cancer.
- Trial name
- PICK-NEPC (NCT03179410)
- Testing
- Avelumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Andrew J. Armstrong, MD
Prostate Cancer
68Ga-THP-PSMA PET/CT Imaging in High Risk Primary Prostate Cancer or Biochemical Recurrence of Prostate Cancer
This will be an open-labelled, single centre study in the UK. The study group will include 60 patients with three groups of patients being studied.
- Trial name
- PRONOUNCED (NCT03617588)
- Testing
- Gallium-68 THP-PSMA
- Where
- 4 sites in United Kingdom
- Volunteers
- 49 people
- Sponsor
- Theragnostics Ltd
Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8
Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer
This phase II trial studies how well apalutamide and gonadotropin-releasing hormone analog with or without abiraterone acetate work in treating participants with prostate cancer prior to surgery.
- Conditions
- Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8
- Trial name
- NCT03279250
- Testing
- Abiraterone Acetate, Apalutamide, Gonadotropin-releasing Hormone Analog
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate Cancer
This phase IV trial studies how well an investigational scan (18F-fluciclovine PET-CT) works for the measurement of therapeutic response in patients with prostate cancer that has spread to other places in the body (metastatic).
- Trial name
- NCT04134208
- Testing
- Computed Tomography, Fluciclovine F18, Positron Emission Tomography
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
A Phase II, Prospective Study of MRI in the Reclassification of Men Considering Active Surveillance in Prostate Cancer
Some men newly diagnosed with prostate cancer do not require immediate treatment. Rather, they can be followed closely with regular physical exams, blood work and repeated biopsies of the prostate.
- Trial name
- NCT01858688
- Testing
- Multiparametric MRI, Prostate biopsy
- Where
- 2 sites in United States
- Volunteers
- 101 people
- Sponsor
- Dana-Farber Cancer Institute
Recurrent Prostate Cancer, Stage IV Prostate Cancer
Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer
This phase II trial is studying how well vorinostat works in treating patients with progressive metastatic prostate cancer. Drugs used in chemotherapy, such as vorinostat, work in different ways to stop the growth of tumor cells…
- Trial name
- NCT00330161
- Testing
- vorinostat, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.
The purpose of this study is to assess the benefit of immediate hormonal treatment after Radical Prostatectomy in Chinese and Russian patients with high risk prostate cancer.
- Trial name
- PRIORITI (NCT01753297)
- Testing
- Triptorelin 11.25 mg
- Where
- 18 sites in China, Russia
- Volunteers
- 226 people
- Sponsor
- Ipsen
Ovary Cancer, Cervix Cancer
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
The purpose of the trial is to establish the tolerability of HuMax-TF-ADC in a mixed population of patients with specified solid tumors.
- Conditions
- Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer
- Trial name
- NCT02001623
- Testing
- Tisotumab Vedotin (HuMax-TF-ADC)
- Where
- 29 sites in United States, Belgium and 3 more
- Volunteers
- 195 people
- Sponsor
- Seagen Inc.
Prostatic Neoplasms, Prostate Cancer
18F-DCFBC PET/CT in Prostate Cancer
Background: Prostate cancer is the second leading cause of cancer deaths in American men. A chemical called a radiotracer helps doctors get images of this type of cancer.
- Trial name
- NCT02190279
- Testing
- 18F DCFBC, Sodium (Na)18F positron emission tomography (PET)/computed tomography (CT)
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Hydroxychloroquine in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer
This phase II trial studies how well hydroxychloroquine works in treating patients with previously treated prostate cancer. Autophagy destroys proteins and other substances in cells and may be used by prostate cancer cells to…
- Trial name
- NCT00726596
- Testing
- hydroxychloroquine
- Where
- 5 sites in United States
- Volunteers
- 64 people
- Sponsor
- Rutgers, The State University of New Jersey
Prostate Cancer
Telephone Counseling: Men With Prostate Cancer & Partners
The purpose of this project is to test a telephone delivered educational support program versus an education only program for improving symptom management and quality of life in men with prostate cancer and their partners.
- Trial name
- NCT00822510
- Testing
- Telephone Interpersonal Counseling, Telephone delivered education only
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- University of Arizona
Prostate Cancer
Study of Hypofractionated Proton Beam Radiation Therapy for Prostate Cancer
The purpose of this study is to determine hypofractionated conformal proton beam radiation therapy of prostate cancer can achieve similar treatment benefits as our current institutional standard with conventional fractionation.
- Trial name
- NCT00831623
- Testing
- Proton Radiation, Proton
- Where
- United States
- Volunteers
- 167 people
- Sponsor
- Loma Linda University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.